Molecular Partners Finalizes License Agreement with Novartis for Ensovibep for COVID-19GlobeNewsWire • 01/18/22
Molecular Partners Reports Disclosure of Major Shareholder as per Swiss Stock Exchange RegulationsGlobeNewsWire • 01/13/22
Novartis To In-License COVID-19 Treatment From Molecular Partners, After Encouraging Mid-Stage DataBenzinga • 01/10/22
Molecular Partners and Novartis Report Positive Topline Data from Phase 2 Study for Ensovibep (MP0420), a DARPin Antiviral Therapeutic for COVID-19GlobeNewsWire • 01/10/22
Novartis and Molecular Partners report positive topline data from Phase 2 study for ensovibep (MP0420), a DARPin antiviral therapeutic for COVID-19GlobeNewsWire • 01/10/22
Wall Street Analysts See a 96% Upside in Molecular Partners AG Sponsored ADR (MOLN): Can the Stock Really Move This High?Zacks Investment Research • 01/06/22
Molecular Partners Announces Collaboration with Novartis to Develop DARPin-Conjugated Radioligand Therapeutic Candidates for OncologyGlobeNewsWire • 12/14/21
Molecular Partners Confirms Ensovibep Retains Neutralization of Omicron Variant of SARS-CoV-2 in Preclinical StudiesGlobeNewsWire • 12/12/21
Molecular Partners Highlights Upcoming Oncology Portfolio Presentations in DecemberGlobeNewsWire • 12/09/21
Molecular Partners Presents Results from a Phase 2a Trial of Ensovibep in 12 COVID-19 Patients at ESWI 2021GlobeNewsWire • 12/06/21
Molecular Partners Announces Research Collaboration with University of Bern to Develop MP0533, a Multispecific DARPin for the Treatment of AMLGlobeNewsWire • 12/03/21
Molecular Partners Says Its COVID-19 Antiviral Still Effective Against Positions Mutated In OmicronBenzinga • 11/30/21
Molecular Partners Confirms Retained Activity of Ensovibep on the Positions Mutated in Emerging Omicron Variant of SARS-CoV-2 In VitroGlobeNewsWire • 11/30/21
Molecular Partners Announces Presentation at the Evercore ISI 4th Annual HealthCONx ConferenceGlobeNewsWire • 11/24/21
See Why Molecular Partners Shares Dropped To 52-Week Low During Tuesday Premarket?Benzinga • 11/16/21
Molecular Partners Provides Update from ACTIV-3 Global Clinical Study of Ensovibep in Patients Hospitalized with COVID-19GlobeNewsWire • 11/16/21
Interim Management Statement Q3 2021 of Molecular Partners: Advancement of COVID-19 Clinical Program and Continued Immuno-Oncology MomentumGlobeNewsWire • 10/28/21